(("clinical guidelines"[Resource Type]) OR "practice guideline"[Public - Books

Result Filters

Results: 20 books (99 items)

Select item 55044521.

Daratumumab (Darzalex SC): CADTH Reimbursement Recommendation: Indication: In combination with bortezomib, cyclophosphamide, and dexamethasone for the treatment of adult patients with newly diagnosed light chain (AL) amyloidosis [Internet].

Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2022 Feb.

Top results in this book Table of Contents

Select item 56000402.

Vutrisiran (Amvuttra): CADTH Reimbursement Recommendation: Indication: For the treatment of stage 1 or stage 2 polyneuropathy in adult patients with hereditary transthyretin-mediated amyloidosis [Internet].

Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2024 Feb.

Top results in this book Table of Contents

Select item 28215243.

PDQ Cancer Information Summaries [Internet].

Bethesda (MD): National Cancer Institute (US); 2002-.

Top results in this book Table of Contents

Select item 44670724.

Cystic Fibrosis: Diagnosis and management.

National Guideline Alliance (UK).

London: National Institute for Health and Care Excellence (NICE); 2017 Oct 25. (NICE Guideline, No. 78.)

Top results in this book Table of Contents

Select item 48762485.

CADTH Canadian Drug Expert Committee Recommendation: Patisiran (Onpattro — Alnylam Netherlands BV): Indication: For the treatment of polyneuropathy in adult patients with hereditary transthyretin-mediated amyloidosis (hATTR amyloidosis) [Internet].

Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2019 Jul.

Top results in this book Table of Contents

Select item 56174746.

Selinexor (Xpovio): CADTH Reimbursement Recommendation: Indication: Multiple myeloma [Internet].

Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2022 Aug.

Top results in this book Table of Contents

Select item 56350287.

$Teclistamab (Tecvayli): CADTH Reimbursement Recommendation: Indication: For the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least 3 prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody, and who have demonstrated disease progression on the last therapy [Internet].$

Teclistamab (Tecvayli): CADTH Reimbursement Recommendation: Indication: For the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least 3 prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody, and who have demonstrated disease progression on the last therapy [Internet].

Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2024 Apr.

Top results in this book Table of Contents

Select item 55022988.

$Isatuximab (Sarclisa): CADTH Reimbursement Recommendation: Indication: In combination with carfilzomib and dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma who have received 1 to 3 prior lines of therapy [Internet].$